How is AI revolutionizing oncology data? Find out in this special 'New Frontiers' episode (aired on Bloomberg) that explores the evolution of AI-powered oncology Data Intelligence with @Larvol. #LARVOL #BloombergTV #NewFrontiers #Tech #Healthcare #Oncology #CancerResearch

Ajax Therapeutics Receives Orphan Drug Designation from the U.S. FDA for AJ1-11095 for the Treatment of Myelofibrosis https://t.co/8h8PRjXkhV Learn more 👉 https://t.co/QIxuqGkJB3 #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #FDA #FDAApproval #Myelofibrosis

Our average cost per month for CrowdHealth hit its lowest EVER in 2025!!! $140.42/month for singles <55 (down 13% vs '24) $225.83/month for singles 55+ (down 17% vs '24) $476.25/month for families of 4 (down 11% vs '24) If you are looking for an affordable alternative to health

Top Multiple Myeloma Oncologists from @ASH_hematology 2025 Explore more insights and data from #ASH25: https://t.co/5urS4cYVjA #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ASH2025 #Hematology #HEMSM #ClinicalTrials #MultipleMyeloma #MMSM | @VincentRK |

Top Leukemia Oncologists from @ASH_hematology 2025 Explore more insights and data from #ASH25: https://t.co/5urS4cYVjA #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ASH2025 #Hematology #HEMSM #ClinicalTrials #Leukemia #LEUSM | @TalhaBadarMD | @Papa_Heme |

Top Lymphoma Oncologists from @ASH_hematology 2025 Explore more insights and data from #ASH25: https://t.co/5urS4cYnu2 #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #ASH2025 #Hematology #HEMSM #ClinicalTrials #Lymphoma #LYMSM | @majorajay | @JohnPLeonardMD |

Watching those Tec/Dara vs Cilta-Cel PFS curves 👀📈 — honestly, a head-to-head RCT might be all we need to prove Tec/Dara has the edge… IMHO 🤷‍♂️🔥 #mmsm #myeloma #MedEd #MedTwitter #USMIRC @US_HMC @USMIRCNEWS @MedwatchKate @Larvol @oncodaily

🧵 MajesTEC-3 Trial — Teclistamab + Daratumumab in RRMM A breakthrough Phase 3 trial reshaping post-lenalidomide treatment! #ASH25 #mmsm #Myeloma #MedEd #USMIRC @USMIRCNEWS @US_HMC @oncodaily @MedwatchKate @Larvol

GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA https://t.co/zziumQWSyZ Learn more 👉 https://t.co/2uAj6nJNtw #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ADCs #LungCancer #SCLC

@SABCSSanAntonio 2025: From the floor - Day 1 Explore more insights and data from #SABCS25: https://t.co/nG3rXwOJ5Q #LARVOL #SABCS2025 #Oncology #CancerResearch #CancerData #Oncologylnsights #BreastCancer #BCSM | @brunolarvol | @one_interrobang

Ahead of @SABCSSanAntonio 2025, we asked leading AI models to predict hazard ratio outcomes for three of the most closely watched breast cancer trials, with no results publicly disclosed to date. Here’s the AI consensus (HR < 1 favors experimental). Which trial do you think

🔄 Refreshed data for CR109234 trial from American Society of Hematology 2025 in 4L+ R/R MM. BsAbs landscape adapted from Dr. Al-Ola Abdallah, MD (@Abdallah81MD) Original publication:  https://t.co/yQ2JMo3LSK Updated Landscape ⬇️ Explore more insights and data from #ASH25:

🔄 Refreshed iMMagine-1 data from @ASH_hematology 2025 in 2L+ R/R MM. Landscape adapted from Dr. Rahul Banerjee, MD (@RahulBanerjeeMD). Original publication: https://t.co/0reUjfCJDY Updated Landscape ⬇️ Explore more insights and data from #ASH25: https://t.co/5urS4cYVjA

🔄 Refreshed data for DREAMM8 from @ASH_hematology 2025. Original publication: https://t.co/ShEWmJfk1i Updated Landscape ⬇️ Explore more insights and data from #ASH25: https://t.co/5urS4cYVjA #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #Hematology #HEMSM

🔄 Refreshed data for Jupiter06 trial from @myESMO - Asia 2025 in First-Line ESCC. Landscape adapted from Dr Akhil Santhosh (MD, DM Med Onc, MRCP UK) (@tuttsakhil) Original publication:  https://t.co/24i8a9GMcg Updated Landscape ⬇️ Stay updated on oncology conferences, top

Recap of Day 3 of @ASH_hematology 2025: Top Trials Explore more insights and data from #ASH25: https://t.co/5urS4cYVjA #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #Hematology #HEMSM #ClinicalTrials | @TalhaBadarMD | @majorajay | @PriyaSriRajah | @LeukDocJZ

Recap of Day 2 of @ASH_hematology 2025: Top Trials Explore more insights and data from #ASH25: https://t.co/5urS4cYVjA #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights #Hematology #HEMSM #ClinicalTrials | @RahulBanerjeeMD | @HadidiSamer | @majorajay |

CHM CDH17 granted FDA Orphan Drug Designation for Gastric Cancer https://t.co/PwosecP7mR Learn more 👉 https://t.co/Kh8M9x0mjb #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #FDA #FDAApproval #ClinicalTrials #GastricCancer #GICSM

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA https://t.co/ftkwDBMwmr Learn more 👇 https://t.co/b2r5L61IST https://t.co/b78053mnXa #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights

Top oncologists to follow for #BreastCancer updates during the @SABCSSanAntonio 2025, highlighted by @Larvol CLIN. Explore more insights and data from #SABCS25: https://t.co/nG3rXwOJ5Q #LARVOL #SABCS2025 #Oncology #CancerResearch #CancerData #Oncologylnsights #BreastCancer

Top #BreastCancer trials to watch ahead of @SABCSSanAntonio 2025, based on oncologists’ posts on 𝕏 — curated by @Larvol CLIN. Explore more insights and data from #SABCS25: https://t.co/nG3rXwOJ5Q #LARVOL #SABCS2025 #Oncology #CancerResearch #CancerData #Oncologylnsights